دورية أكاديمية
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation
| العنوان: | Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation |
|---|---|
| المؤلفون: | Costa, Luciano J., Iacobelli, Simona, Pasquini, Marcelo C., Modi, Riddhi, Giaccone, Luisa, Bladé, Joan, Schönland, Stefan, Evangelista, Andrea, Pérez-Simón, José A., Hari, Parameswaran, Brown, Elizabeth E., Giralt, Sergio A., Patriarca, Francesca, Stadtmauer, Edward A., Rosiñol, Laura, Krishnan, Amrita Y., Gahrton, Gösta, Bruno, Benedetto |
| بيانات النشر: | Springer Nature |
| سنة النشر: | 2020 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Cancer immunotherapy, Myeloma, Phase III trials |
| الوصف: | Contrary to tandem autologous transplant (auto-auto), autologous followed by reduced intensity conditioning allogenic transplantation (auto-allo) offers graft-versus-myeloma (GVM) effect but with higher toxicity. Trials comparing these two strategies relied on availability of HLA-matched sibling donors for arm allocation (biological randomization) and yielded conflicting results. A pooled analysis of multiple trials with extended follow up provides an opportunity to compare these strategies. We obtained individual patient data from participants of four trials comparing auto-auto vs. auto-allo after induction therapy. There were 899 patients in auto-auto and 439 in auto-allo. Median follow up of survivors was 118.5 months. Median overall survival (OS) was 78.0 months in auto-auto and 98.3 months in auto-allo (HR = 0.84, P = 0.02). OS was 36.4% vs. 44.1% at 10 years (P = 0.01) for auto-auto and auto-allo, respectively. Progression-free survival was also improved in auto-allo (HR = 0.84, P = 0.004). Risk of non-relapse mortality was higher in auto-allo (10 year 8.3% vs. 19.7%, P < 0.001), while risk of disease progression was higher in auto-auto (10 year 77.2% vs. 61.6%, P < 0.001). Median post relapse survival was 41.5 months in auto-auto and 62.3 months in auto-allo (HR = 0.71, P < 0.001). This supports the existence of durable GVM effect enhancing myeloma control with subsequent therapies. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 0268-3369 1476-5365 |
| العلاقة: | http://dx.doi.org/10.1038/s41409-020-0887-4Test; Sí; Bone Marrow Transplantation 55: 1810-1816 (2020); http://hdl.handle.net/10261/237611Test |
| DOI: | 10.1038/s41409-020-0887-4 |
| الإتاحة: | https://doi.org/10.1038/s41409-020-0887-4Test http://hdl.handle.net/10261/237611Test |
| حقوق: | none |
| رقم الانضمام: | edsbas.2E5622D9 |
| قاعدة البيانات: | BASE |
| تدمد: | 02683369 14765365 |
|---|---|
| DOI: | 10.1038/s41409-020-0887-4 |